Lilly's stock leads S&P 500 losers as Mounjaro, Zepbound sales to miss forecasts
Shares of Eli Lilly were taking a 6.9% hit toward a two-month low in recent trading, enough to make them the S&P 500's biggest decliner. The problem is that the drug giant provided fourth-quarter revenue guidance that was below Wall Street expectations,
People claim the viral "natural Mounjaro" drink — honey, lemon, water, and ginger — makes you lose weight. Here's what an ...
Up to 3.4 million eligible patients could benefit from the medication that treats type 2 diabetes and aids weight loss ...
A GP has explained, week by week, what changes you will see - including how much weight you will lose in the first month ...
Research reveals groundbreaking results about Mounjaro and Ozempic in weight loss treatment. Here's what you need to know ...
Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...
24/7 Wall St. on MSN1d
Down 23%, Is This Dividend Giant a Buy After GLP-1 Sales Miss?Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...
A mom of two is getting her exercise by cleaning her house. It's something Melissa Floro says she didn't have the energy to ...
Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...
Dolores Catania will be on 'The Traitors' season three. Here's what she said about her 20-pound weight loss, including ...
Evening Standard on MSN2d
Celebrities who’ve used Ozempic: Oprah Winfrey, James Corden, and moreWhile talk show queen Oprah Winfrey has declined to name the brand she uses, she’s among the Hollywood stars who have been ...
The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback